A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β-1a

Neurology

Volumn 55, Issue 2, 2000, Pages 185-192

  Simon, J H ^a   Lull, J ^b   Jacobs, L D ^c   Rudick, R A ⁱ   Cookfair, D L ^d   Herndon, R M ^e   Richert, J R ^f   Salazar, A M ^g   Sheeder, J ^a   Miller, D ^a   McCabe, K ^a   Serra, A ^a   Campion, M K ^b   Fischer, J S ⁱ   Goodkin, D E ^h   Simonian, N ^b   Lajaunie, M ^a   Wende, K ^d   Martens Davidson, A ^d   Kinkel, R P ⁱ   Munschauer III, F E ^c   more..

^a UNIVERSITY OF COLORADO   (United States)

^b BIOGEN   (United States)

^c BUFFALO GENERAL HOSPITAL   (United States)

^d Millard Fillmore Gates Circle Hospital   (United States)

^e LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^g WALTER REED ARMY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE;

EID: 0033852514     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.2.185     Document Type: Article

References (30)

1. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
2. Simon JH. Magnetic resonance imaging of multiple sclerosis lesions: measuring outcome in treatment trials. West J Med 1996;164:502-509.
3. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669.
4. Nesbit GM, Forbes GS, Scheithauer BW, et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991; 180:467-474.
5. Simon JH. Contrast enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. JMRI 1997;7:29-37.
6. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion: a quantitative MRI and electron microscopic study. Brain 1991;114:1271-1280.
7. Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991;114:1013-1023.
8. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119: 2009-2019.
9. Simon JH, Jacobs L, Campion M, et al. A longitudinal study of brain atrophy in relapsing MS. Neurology 1999;53:139-148.
10. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51:234-238.
11. Filippi M, Campi A, Colombo B, et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996;243:502-505.
12. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67.
13. Loevner LA, Grossman RI, McGowan KN, Cohen JA. Characterization of multiple sclerosis plaques with T1-weighted MRI and quantitative magnetization transfer. AJNR Am J Neuroradiol 1995;16:1473-1479.
14. Arnold DL, Wolinsky JS, Matthews PM, Falini A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:S94-S101.
15. Truyen L, van Waesberghe JHTM, Barkof F, et al. Accumulation of hypointense lesions ("blackholes℧) on T1 spin echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476.
16. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/short TE (T1 weighted) spin echo images. Neurology 1995;45:1684-1690.
17. van Waesberghe JH, Castelijns JA, Scheltens P, et al. Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. Magn Reson Imaging 1997;15:155-162.
18. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288.
19. van Walderveen, Barkhof F, Pouwels PJW, et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46:79-87.
20. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler 1995;1:118-135.
21. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
22. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-363.
23. Simon JH, Jacobs LD, Campion M. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
24. Simon JH. From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmun 1999;98:7-15.
25. van Waesberghe JHTM, van Walderveen MAA, Castelijns JA, et al. MR patterns of lesion development in MS: longitudinal observations using T1 spin echo and MT imaging. AJNR Am J Neuroradiol 1998;1:675-683.
26. Giugni E, Pozzilli C, Bastianello S, et al. MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 1997; 3:221-225.
27. O'Riordan JI, Gawne Cain W, Coles A, et al. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre-versus post-contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler 1998;4:408-412.
28. Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287.
29. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339.
30. Tubridy N, Coles AJ, Molyneux P, et al. Secondary progressive MS: the relationship between short-term MRI activity and clinical features. Brain 1998;121:225-231.